S. Kahraman Et Al. , "223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study," ESMO OPEN , vol.9, no.Volume 9 - Issue S4 - 2024, pp.31-32, 2024
Kahraman, S. Et Al. 2024. 223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study. ESMO OPEN , vol.9, no.Volume 9 - Issue S4 - 2024 , 31-32.
Kahraman, S., Erul, E., Gumusay, O., Guven, D., Aksoy, S., Basaran, G., ... Seyyar, M.(2024). 223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study. ESMO OPEN , vol.9, no.Volume 9 - Issue S4 - 2024, 31-32.
Kahraman, S. Et Al. "223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study," ESMO OPEN , vol.9, no.Volume 9 - Issue S4 - 2024, 31-32, 2024
Kahraman, S. Et Al. "223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study." ESMO OPEN , vol.9, no.Volume 9 - Issue S4 - 2024, pp.31-32, 2024
Kahraman, S. Et Al. (2024) . "223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study." ESMO OPEN , vol.9, no.Volume 9 - Issue S4 - 2024, pp.31-32.
@article{article, author={S. Kahraman Et Al. }, title={223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study}, journal={ESMO OPEN}, year=2024, pages={31-32} }